These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30116943)

  • 21. Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
    Khan F; Ottensmeier C; Popat S; Dua D; Dorey N; Ellis S; Szabo M; Upadhyay S; Califano R; Chan S; Lee L; Ali CW; Nicolson M; Bates AT; Button M; Chaudhuri A; Mulvenna P; Shaw HM; Danson SJ
    Eur J Cancer; 2014 Jul; 50(10):1717-1721. PubMed ID: 24726055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
    Hirsh V
    BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].
    Tao H; Guo L; Tang J; Zhu Y; Xu L; Meng Q; Wu W; Li M; Wu W; Tong L; Wu H; Shi L; Liu Z
    Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):342-6. PubMed ID: 24758910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
    Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcopenia as a predictor of initial administration dose of afatinib in patients with advanced non-small cell lung cancer.
    Nie X; Zhang P; Gao JY; Cheng G; Liu W; Li L
    Thorac Cancer; 2021 Jun; 12(12):1824-1830. PubMed ID: 33951292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.
    Ricciuti B; Baglivo S; De Giglio A; Chiari R
    Ther Adv Respir Dis; 2018; 12():1753466618808659. PubMed ID: 30355049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Respir Investig; 2016 Nov; 54(6):468-472. PubMed ID: 27886859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
    Tanaka H; Taima K; Tanaka Y; Itoga M; Ishioka Y; Nakagawa H; Baba K; Hasegawa Y; Takanashi S; Tasaka S
    Med Oncol; 2018 Feb; 35(3):34. PubMed ID: 29423683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
    Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
    Arriola E; Reguart N; Artal A; Cobo M; García-Campelo R; Esteban E; Rodríguez MC; García-Muret MP
    Future Oncol; 2015; 11(2):267-77. PubMed ID: 25236437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
    Lee Y; Lee KH; Lee GK; Lee SH; Lim KY; Joo J; Go YJ; Lee JS; Han JY
    Cancer Res Treat; 2017 Oct; 49(4):1001-1011. PubMed ID: 28111428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
    Passaro A; Di Maio M; Del Signore E; Gori B; de Marinis F
    Clin Lung Cancer; 2014 Jul; 15(4):307-12. PubMed ID: 24954231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of afatinib for the treatment of non-small cell lung cancer.
    Barron F; de la Torre-Vallejo M; Luna-Palencia RL; Cardona AF; Arrieta O
    Expert Opin Drug Saf; 2016 Nov; 15(11):1563-1572. PubMed ID: 27633264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
    Arrieta O; Vega-González MT; López-Macías D; Martínez-Hernández JN; Bacon-Fonseca L; Macedo-Pérez EO; Ramírez-Tirado LA; Flores-Estrada D; de la Garza-Salazar J
    Lung Cancer; 2015 Jun; 88(3):282-8. PubMed ID: 25882778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
    Giordano P; Manzo A; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Daniele G; Normanno N; Carillio G; Rocco G; Bianco R; Perrone F; Morabito A
    Crit Rev Oncol Hematol; 2016 Jan; 97():143-51. PubMed ID: 26318094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    De Grève J; Moran T; Graas MP; Galdermans D; Vuylsteke P; Canon JL; Schallier D; Decoster L; Teugels E; Massey D; Chand VK; Vansteenkiste J
    Lung Cancer; 2015 Apr; 88(1):63-9. PubMed ID: 25682316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.